• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button Iconsarepta

sarepta

FDA Sarepta Drug Approval Controversy
NewslettersDoes the FDA need to slow its drug approval roll?
By Sy MukherjeeJanuary 22, 2020
Sarepta Stock Roche Deal
HealthControversial Biotech Sarepta Keeps Up Unlikely Win Streak With $1.15 Billion Roche Deal
By Sy MukherjeeDecember 23, 2019
Duchenne Sarepta FDA
NewslettersFDA Approves Sarepta Duchenne Drug in Stunning Reversal
By Sy MukherjeeDecember 13, 2019
Businessman with Duchenne muscular dystrophy in a motorized wheelchair working in an office
HealthWhy Sarepta Stock Skyrocketed 40% Today
By Sy MukherjeeJune 19, 2018
Businessman with Duchenne muscular dystrophy in a motorized wheelchair working in an office
HealthThis Controversial Biotech May Yet Defy Its Skeptics
By Sy MukherjeeSeptember 6, 2017
A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris
HealthDrug Giant Sanofi May Be Getting Ready to Buy Up This Rare Disease Company
By Sy MukherjeeApril 28, 2017
Gilead Just Paid $125 Million to Nab a Big Market Advantage
HealthGilead Just Paid $125 Million to Nab a Big Market Advantage
By Sy MukherjeeFebruary 21, 2017
Businessman with Duchenne muscular dystrophy in a motorized wheelchair working in an office
HealthDrug Company Hits Pause on Launching an $89,000 Muscular Dystrophy Drug After Backlash
By Sy MukherjeeFebruary 13, 2017
This Pharma Company Is Selling a Decades-old Drug to Treat Muscular Dystrophy for $89,000
HealthThis Pharma Company Is Selling a Decades-old Drug to Treat Muscular Dystrophy for $89,000
By Sy MukherjeeFebruary 10, 2017
Sarepta Therapeutics New Global Headquarters
HealthInsurers are Rebelling Against the FDA’s Most Controversial 2016 Drug Approval
By Sy MukherjeeDecember 14, 2016
Trading On The Floor Of The NYSE As U.S. Stocks Slide Amid Speculation On Tighter Monetary Policy
HealthWhy This Controversial Biotech Stock Just Soared More Than 88%
By Sy MukherjeeNovember 11, 2016
Businessman with Duchenne muscular dystrophy in a motorized wheelchair working in an office
HealthThe FDA’s Most Controversial Drug Approval of the Year Just Hit a Huge Snag
By Sy MukherjeeOctober 7, 2016
Conversation on Child Cures
HealthThe FDA Just Made Its Most Controversial Drug Approval of the Year
By Sy MukherjeeSeptember 19, 2016
483106863
HealthThis Drug Company’s Shares Are Up 20% Today
By ReutersMay 25, 2016
Businessman with Duchenne muscular dystrophy in a motorized wheelchair working in an office
HealthThis Rare Children’s Disease Drug Is Pitting Patients Against the FDA
By Sy MukherjeeApril 26, 2016
1
  • 1
1
Most Popular
Real Estate
Gen Z fled San Francisco for Texas and Florida. Now they’re turning ‘welcomer cities’ into the next big tech townsplaceholder alt text
By Fortune EditorsApril 2, 2026
Success
Major 4-day workweek study suggests that when we work 5 days we spend one doing basically nothingplaceholder alt text
By Fortune EditorsApril 2, 2026
Personal Finance
Current price of oil as of April 2, 2026placeholder alt text
By Fortune EditorsApril 2, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.